Muscular dystrophy startup secures SBIR grant to continue developing myostatin inhibitor
With a new $300,000 Phase I SBIR grant from the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases, biotech startup Milo Biotechnology will march forward with development and testing of its follistatin therapy for muscular dystrophy. Its lead candidate, AAV1-FS344, is a gene therapy intended to up-regulate follistatin, a protein that blocks myostatin, […]